A detailed history of First Trust Advisors LP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 10,676 shares of NTLA stock, worth $92,881. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,676
Previous 10,228 4.38%
Holding current value
$92,881
Previous $95,000 93.68%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$9.88 - $17.76 $4,426 - $7,956
448 Added 4.38%
10,676 $184,000
Q2 2025

Aug 13, 2025

BUY
$6.28 - $9.67 $64,231 - $98,904
10,228 New
10,228 $95,000
Q1 2024

May 13, 2024

BUY
$23.82 - $32.8 $1.23 Million - $1.69 Million
51,438 New
51,438 $1.42 Million
Q3 2023

Nov 13, 2023

BUY
$31.62 - $45.78 $1.05 Million - $1.52 Million
33,208 New
33,208 $1.05 Million
Q1 2022

May 13, 2022

SELL
$58.27 - $118.99 $4.15 Million - $8.48 Million
-71,282 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$100.76 - $138.36 $587,027 - $806,085
5,826 Added 8.9%
71,282 $8.43 Million
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $647,951 - $865,338
-4,895 Reduced 6.96%
65,456 $8.78 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $1.52 Million - $4.04 Million
-24,946 Reduced 26.18%
70,351 $11.4 Million
Q1 2021

May 14, 2021

BUY
$46.59 - $83.68 $1.18 Million - $2.12 Million
25,283 Added 36.11%
95,297 $7.65 Million
Q4 2020

Feb 02, 2021

BUY
$18.83 - $63.53 $1.32 Million - $4.45 Million
70,014 New
70,014 $3.81 Million
Q1 2019

May 09, 2019

SELL
$12.79 - $17.62 $861,048 - $1.19 Million
-67,322 Closed
0 $0
Q4 2018

Feb 07, 2019

SELL
$11.39 - $27.13 $1.06 Million - $2.52 Million
-92,981 Reduced 58.0%
67,322 $919,000
Q3 2018

Oct 25, 2018

BUY
$25.78 - $32.6 $1.44 Million - $1.82 Million
55,798 Added 53.39%
160,303 $4.59 Million
Q2 2018

Aug 02, 2018

BUY
$20.02 - $30.79 $2.09 Million - $3.22 Million
104,505 New
104,505 $2.86 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $661M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.